Home > Insider Trading > Filing (0000905718-18-000554)

Filing Details

Accession Number:: 0000905718-18-000554
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-06-07 16:36:39
Reporting Period:: 2018-06-05

Accepted Time:: 2018-06-07 16:36:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1674416	Crispr Therapeutics Ag	CRSP	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1252524	Von Kurt Emster	C/O Crispr Therapeutics, Inc. 610 Main Street Cambridge MA 02139		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2018-06-05	2,000	$5.75	19,236	No	4	X	Indirect	By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005
Common Stock	Disposition	2018-06-05	920	$12.51	18,316	No	4	S	Indirect	By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	X	Indirect	By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005
No	4	S	Indirect	By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrant (right to buy)	Disposition	2018-06-05	2,000	$0.00	2,000	$5.75

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2013-09-30	2018-09-30	No	4	X	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	90,000	Direct
Common Stock	273,417	Indirect	See footnotes

Footnotes

On June 5, 2018, Kurt von Emster (the "Reporting Person") on behalf of the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005, exercised a warrant to purchase 2,000 shares of CymaBay Therapeutics, Inc. ("CBAY") common stock for $5.75 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in CBAY's withholding of 920 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 1,080 shares. CBAY also paid $9.47 to the Reporting Person in lieu of a fractional share.
Shares are held by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE" together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth.
From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.